Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821684) titled 'A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AbbVie
Condition:
Non-Squamous Non-Small Cell Lung Cancer
Intervention:
Drug: Telisotuzumab Adizutecan
Drug: Docetaxel
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: January 6,...